Strategic Partner

A stable source of capital for companies
  • A funding alternative at a reasonable cost.
  • Investors who have committed capital to Bergen’s funds include family offices, funds of funds and foundations, many with longer-term investment horizons and a long history of investing with Bergen.
  • The Bergen group of companies is comprised of a stable and effective nine-person origination, investment and operations team in the United States, the UK and Australia, with backgrounds in law, investment banking and funds management.
Versatile and creative funding solutions
  • Bergen provides financing for working capital needs, growth, acquisitions and a variety of special situations, all as a principal investor.
  • We work closely with management teams to structure transactions that align the interests of all stakeholders.
  • Bergen’s multiple funds allow us to use a variety of investment instruments tailored appropriately to each unique situation, including equity and convertible securities.
  • Our check sizes range from hundreds of thousands of dollars to high double-digit millions of dollars, per transaction, either as a single lump sum or spread among multiple tranches.
More than just capital
  • We have contacts that can assist our portfolio companies in meeting their goals – industry partners and specialists, other co-investors, acquirers, media, investment banks, legal, and more.
  • The Bergen companies have offices around the globe – New York, London and Sydney – and a wide network in the United States, Europe, Australia and Asia.
  • For private portfolio companies, we help source qualified board and management candidates to complement and augment established management teams.
Prima BioMed Limited
(ASX:PRR, now ASX:IMM)

Bergen entered into an agreement for a US$37.4 million investment with Prima BioMed, an ASX-listed biotechnology company developing oncology therapeutics in October 2014.

Prima BioMed’s market capitalization increased from approximately A$47 million to approximately A$407 million during the term of the Bergen investment.